Outcome of Adolescents and Young Adults Compared With Pediatric Patients With Acute Myeloid and Promyelocytic Leukemia

Conclusion Our analysis shows AYAs with AML have worse EMR and OS compared with pAMLs. AYAs with APL and pAPLs have similar outcomes. To our knowledge, this is the first study reporting outcomes of AYAs with APL and pAPLs using a large population-based registry and their comparison with same age patients with AML. Micro-Abstract Studies on the outcome of adolescents and young adults (AYAs) with acute myeloid leukemia (AML) and acute promyelocytic leukemia (APL) are limited. We compared outcomes of AYAs (age, 19-30 years) and pediatric (age, 0-18 years) patients with AML and APL using the Surveillance, Epidemiology, and End Results-18 registry. AYA patients with AML have worse early mortality and overall survival compared with pediatric patients with AML, whereas AYA and pediatric patients with APL have similar outcomes.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research